Q&A

Androgen Deficiency Syndrome: A Rational Approach to Male Hypogonadism

Author and Disclosure Information

 

During a routine physical examination, a 65-year-old man wants to find out if he has “Low T.” He complains of fatigue, decreased libido, and erectile dysfunction (ED) for the past five years. He has a history of type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, and chronic low back pain. His current medications include metformin, glipizide, lisinopril, atorvastatin, and hydrocodone for back pain. Given these clinical features, the next step will be to find out if he has hypogonadism (androgen ­deficiency).

The Endocrine Society defines hypogonadism as a clinical syndrome in which the testes produce insufficient testosterone as a consequence of an interruption of the hypothalamic-­pituitary-testicular axis. Although prevalence is high in older men, the Endocrine Society does not recommend screening the general population for hypogonadism.1 Rather, screening should be limited to patients with clinical conditions associated with high prevalence of hypogonadism. Of note, approximately 30% of adults with type 2 diabetes have a subnormal testosterone concentration.2

Q: What is pertinent in the history?

The first step in evaluation of hypogonadism is a detailed history. Signs and symptoms such as decreased libido, hot flashes, decreased shaving frequency, breast enlargement/tenderness, and decreased testicular size are highly suggestive of hypogonadism. Other, less specific signs and symptoms include dysthymia, poor concentration, sleep disturbances, fatigue, reduction in muscle strength, and diminished work performance.

If these signs and symptoms are present, the likelihood of hypogonadism is high and further evaluation is needed.1,3 Note any history of alcoholism, liver problems, and testicular trauma or surgery.

A detailed medication history is also important. Some medications, such as opiates, can affect the release of gonadotropins. Among men taking long-term opiates for chronic noncancer pain, the prevalence of hypogonadism is 75%.4 Other drugs, such as spironolactone, can block the androgen effect and lead to hypogonadism.1

Recent reports have suggested an association between testosterone replacement therapy and increased cardiovascular events, making a detailed cardiovascular history essential.5,6 One study found that men ages 75 and older with limited mobility and other comorbidities who used testosterone gel had an increased risk for cardiovascular events.7 Therefore, clinicians need to be cognizant of this risk when considering testosterone therapy for their patients.

On the next page: Physical exam, lab tests, and treatments >>

Pages

Recommended Reading

Coronary Artery Calcification Can Guide Aspirin Therapy
Clinician Reviews
When to Screen for Celiac Disease in Hypothyroidism
Clinician Reviews
Women’s Health Initiative Study Netted $37 Billion in Savings
Clinician Reviews
New Option for Severe Hypertriglyceridemia
Clinician Reviews
Evolocumab Lowers LDL-C With No Effect on Glucose Metabolism
Clinician Reviews
Obese Teens Heading for Bariatric Surgery Already Show Kidney Damage
Clinician Reviews
SLGT2 Inhibitors Show Promise in Renal Protection
Clinician Reviews
Insulin Perturbations Seen in Nondiabetic Patients With NAFLD
Clinician Reviews
Atypical Presentation of Anorexia in Men
Clinician Reviews
Drivers of Thyroidectomy Readmission Risk
Clinician Reviews